| Muckle-Wells Syndrome
Ilaris vs Arcalyst
Side-by-side clinical, coverage, and cost comparison for muckle-wells syndrome.Deep comparison between: Ilaris vs Arcalyst with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsArcalyst has a higher rate of injection site reactions vs Ilaris based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Arcalyst but not Ilaris, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ilaris
Arcalyst
At A Glance
SC injection
Every 4-8 weeks
IL-1beta antagonist
SC injection
Once weekly
IL-1 blocker
Indications
- Familial Cold Autoinflammatory Syndrome 1
- Muckle-Wells Syndrome
- Cryopyrin-Associated Periodic Syndromes
- TNF receptor-associated periodic fever syndrome (TRAPS)
- Hyperimmunoglobulinemia D
- Familial Mediterranean Fever
- Adult-Onset Still Disease
- Systemic onset juvenile chronic arthritis
- Gout
- Cryopyrin-Associated Periodic Syndromes
- Familial cold urticaria
- Muckle-Wells Syndrome
- INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY
- Recurrent pericarditis
Dosing
Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome 1, Muckle-Wells Syndrome For patients >40 kg: 150 mg SC every 8 weeks; for patients >=15 kg and <=40 kg: 2 mg/kg SC every 8 weeks (inadequate response in pediatric patients: 3 mg/kg every 8 weeks).
TNF receptor-associated periodic fever syndrome (TRAPS), Hyperimmunoglobulinemia D, Familial Mediterranean Fever For patients >40 kg: 150 mg SC every 4 weeks (may increase to 300 mg every 4 weeks if response is inadequate); for patients <=40 kg: 2 mg/kg SC every 4 weeks (may increase to 4 mg/kg every 4 weeks if response is inadequate).
Adult-Onset Still Disease, Systemic onset juvenile chronic arthritis For patients >=7.5 kg: 4 mg/kg (maximum 300 mg) SC every 4 weeks.
Gout 150 mg SC as a single dose; if re-treatment is required, an interval of at least 12 weeks must elapse before a new dose.
Cryopyrin-Associated Periodic Syndromes, Familial cold urticaria, Muckle-Wells Syndrome, Recurrent pericarditis Adults: 320 mg loading dose (two 160 mg SC injections on the same day), then 160 mg SC once weekly; pediatric 12-17 years: 4.4 mg/kg (max 320 mg) loading dose (one or two SC injections), then 2.2 mg/kg (max 160 mg) SC once weekly.
INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY Adults: 320 mg SC once weekly as two injections (max 2 mL each) on the same day at two different sites; pediatric patients >=10 kg: 4.4 mg/kg (max 320 mg) SC once weekly as one or two injections (max 2 mL each).
Contraindications
- Confirmed hypersensitivity to canakinumab or to any of the excipients
—
Adverse Reactions
Most common (>=10%) nasopharyngitis, injection-site reactions, infections, diarrhea, influenza, rhinitis, nausea, headache, abdominal pain, musculoskeletal pain, vertigo, weight increased
Serious serious infections (pneumonia, varicella, sepsis, intra-abdominal abscess, conjunctivitis, pharyngotonsillitis), macrophage activation syndrome, neutropenia
Postmarketing Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Most common Injection-site reactions, upper respiratory tract infection, sinusitis, cough, hypoesthesia
Serious Serious infections, risk of malignancy, hypersensitivity reactions, lipid profile changes, neutropenia
Pharmacology
IL-1beta antagonist; canakinumab is a human monoclonal IgG1/kappa antibody that selectively binds human IL-1beta and neutralizes its activity by blocking its interaction with IL-1 receptors, without binding IL-1alpha or IL-1 receptor antagonist, thereby reducing IL-1beta-driven inflammation in autoinflammatory and crystal-induced diseases.
Rilonacept is an IL-1alpha and IL-1beta cytokine trap that acts as a soluble decoy receptor, blocking IL-1 signaling by preventing IL-1alpha and IL-1beta from interacting with cell surface receptors; it also binds IL-1 receptor antagonist (IL-1ra).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ilaris
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Arcalyst
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Ilaris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Arcalyst
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (2/8) · Qty limit (0/8)
Humana
Ilaris
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (1/3)
Arcalyst
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$30/momo
Ilaris Co-pay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/momo
Kiniksa Pharmaceuticals Copay Assistance Program: ArcalystCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IlarisView full Ilaris profile
ArcalystView full Arcalyst profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.